Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Robert Azelby Insider Profile
4 Followers
Robert Azelby, EVP & CCO at Juno Therapeutics, holds 0.00 shares in Juno Therapeutics (Ticker: JUNO), holds ― shares in Cascadian Therapeutics (Ticker: CASC), holds ― shares in Alder Biopharmaceuticals (Ticker: ALDR).
Robert Azelby Juno Therapeutics (JUNO)EVP & CCO
Juno Therapeutics (JUNO)
EVP & CCO
Not Ranked
Robert Azelby has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Robert Azelby holds in companies
Most Profitable Insider Trade
The most profitable trade made by Robert Azelby
Robert Azelby's Trading History
Juno Therapeutics
Mar 07, 2018
―
Uninformative Sell
―
$0.00
Cascadian Therapeutics
―
―
―
―
Alder Biopharmaceuticals
―
―
―
―
Clovis Oncology
―
―
―
―
Immunomedics
Jun 22, 2020
―
Uninformative Buy
―
$326.66K
Climb Bio
―
President & CEO, Director
―
―
Chinook Therapeutics
―
―
―
―
Cardinal Health
Nov 07, 2024
Director
Uninformative Buy
―
$363.85K
ADC Therapeutics
Jun 18, 2024
Director
Informative Sell
20.22K
$155.30K
List of latest transactions for each holding click on a transaction to see Robert Azelby's performance on stock
You May Also Like
Robert Azelby insider profile FAQ
What is the percentage of profitable transactions made by Robert Azelby?
The percentage of profitable transactions made by Robert Azelby is ―.
What is the average return per transaction made by Robert Azelby?
The average return per transaction made by Robert Azelby is ―.
What stocks does Robert Azelby hold?
Robert Azelby holds: JUNO, CASC, ALDR, CLVSQ, IMMU, CLYM, KDNY, CAH, ADCT stocks.
What was Robert Azelby’s latest transaction?
Robert Azelby latest transaction was an Uninformative Sell of ―.
What was Robert Azelby's most profitable transaction?
Robert Azelby’s most profitable transaction was an Informative Sell of ADCT stock on June 18, 2024. The return on the trade was -8.40%.
What is Robert Azelby's role in Juno Therapeutics?
Robert Azelby's role in Juno Therapeutics is EVP & CCO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.